A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy

Mise à jour : Il y a 5 ans
Référence : NCT01242917

Femme et Homme

Extrait

This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.


Critère d'inclusion

  • Rheumatoid Arthritis